Capricor Therapeutics (NASDAQ:CAPR) Earns Outperform Rating from Analysts at Oppenheimer

Oppenheimer initiated coverage on shares of Capricor Therapeutics (NASDAQ:CAPRFree Report) in a research report released on Friday, Marketbeat Ratings reports. The brokerage issued an outperform rating and a $14.00 price target on the biotechnology company’s stock.

A number of other equities research analysts have also weighed in on the stock. Cantor Fitzgerald reissued an overweight rating and set a $8.00 price objective on shares of Capricor Therapeutics in a report on Tuesday, May 14th. HC Wainwright reissued a buy rating and set a $40.00 price objective on shares of Capricor Therapeutics in a report on Tuesday, May 14th. LADENBURG THALM/SH SH boosted their price objective on shares of Capricor Therapeutics from $24.00 to $25.00 and gave the company a buy rating in a report on Tuesday, May 14th. Finally, StockNews.com lowered shares of Capricor Therapeutics from a hold rating to a sell rating in a report on Tuesday, May 14th. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. According to MarketBeat, Capricor Therapeutics currently has an average rating of Moderate Buy and an average target price of $21.75.

Get Our Latest Stock Analysis on CAPR

Capricor Therapeutics Trading Up 1.6 %

Shares of CAPR stock opened at $6.30 on Friday. The business’s fifty day simple moving average is $5.96 and its 200-day simple moving average is $4.69. The company has a market cap of $200.40 million, a PE ratio of -7.24 and a beta of 4.06. Capricor Therapeutics has a 12-month low of $2.68 and a 12-month high of $8.22.

Capricor Therapeutics (NASDAQ:CAPRGet Free Report) last issued its quarterly earnings results on Thursday, February 29th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.21. The business had revenue of $12.09 million for the quarter, compared to the consensus estimate of $5.80 million. Capricor Therapeutics had a negative return on equity of 231.68% and a negative net margin of 89.72%. On average, equities analysts forecast that Capricor Therapeutics will post -1.17 earnings per share for the current year.

Institutional Trading of Capricor Therapeutics

A number of hedge funds have recently bought and sold shares of CAPR. Citigroup Inc. purchased a new position in shares of Capricor Therapeutics during the 3rd quarter worth approximately $211,000. Jump Financial LLC purchased a new position in shares of Capricor Therapeutics during the 4th quarter worth approximately $258,000. BNP Paribas Financial Markets purchased a new position in shares of Capricor Therapeutics during the 1st quarter worth approximately $40,000. Finally, Vanguard Group Inc. boosted its position in shares of Capricor Therapeutics by 17.2% during the 1st quarter. Vanguard Group Inc. now owns 1,365,903 shares of the biotechnology company’s stock worth $9,274,000 after purchasing an additional 200,499 shares during the period. Institutional investors and hedge funds own 21.68% of the company’s stock.

About Capricor Therapeutics

(Get Free Report)

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.

Read More

Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.